|Bid||3.5200 x 1100|
|Ask||3.6300 x 800|
|Day's Range||3.3600 - 3.5200|
|52 Week Range||1.8500 - 6.6500|
|Beta (3Y Monthly)||4.83|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 13, 2019 - May 17, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.00|
In this analysis, researchers reviewed eight published trials designed in accordance with the Guidance for Industry, “Migraine: Developing Drugs for Acute Treatment”, finalized in February 2018, that recommended using co-primary endpoints of pain freedom and freedom from most bothersome symptom (MBS) at 2-hours post-treatment. Using the placebo response rates from these various trials, the authors were able to calculate required sample sizes for future trials and compare these calculations to the sample sizes actually used in completed trials.
Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of its common stock for gross proceeds of $17.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Zosano. The offering is expected to close on or about April 11, 2019, subject to the satisfaction of customary closing conditions. Cantor Fitzgerald & Co. is the sole book-running manager for the offering. A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on March 27, 2019.
Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Zosano. In addition, Zosano intends to grant to the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, on the same terms and conditions.
Zosano Pharma Corporation , a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2018, as well as recent business highlights.
NEW YORK, NY / ACCESSWIRE / March 14, 2019 / Zosano Pharma Corp. (NASDAQ: ZSAN ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 14, 2019, 2018 at 4:30 ...
FREMONT, Calif., March 11, 2019 -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief.
FREMONT, Calif., March 07, 2019 -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and.
NEW YORK, Feb. 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Nearly every day, headlines are popping up surrounding these innovative companies in the healthcare industry as they tackle the prevalent need for qualitative care. Whereas other industries may have different core values and purposes, healthcare companies are tasked with keeping consumers healthy and amid that responsibility, if done correctly, lies the potential for lucrative opportunities. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Zosano Pharma Corporation (ZSAN), Achieve Life Sciences Inc (ACHV), and Aurora Cannabis Inc (ACB) represent four healthcare companies focused on the advancement of the global healthcare industry.
Biotech and healthcare stocks are loved by traders for their big price moves, which usually happen when a company makes progress (or faces problems) with their developmental products like drugs and devices. Results from Phase I, II and III clinical studies, and FDA or European approvals (and rejections), can send stocks soaring. Recent examples include Amarin Corp's (AMRN) 3X move in one day, or Zosano Pharma Corporations' (ZSAN) 100% rip on recent study results.
ParcelPal Technology Inc (PTNYF) (PKG), Sequans Communications S.A. (SQNS), Zosano Pharma Corporation (ZSAN), and EnSync Inc (ESNC) represent 4 tech stocks on the rise on Thursday. The Company's on-demand delivery platform has garnered notoriety for its ease of use. ParcelPal Technology Inc (PTNYF) (PKG) announced towards the end of last month that the Company had formed a partnership with MADD Canada to aid in the continuous fight to prevent impaired driving.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! The big shareholder groups in Zosano Pharma Corporation (NASDAQ:ZSAN) haveRead More...
Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced the completion of the second and final goal of the long-term safety study for Qtrypta, in which patients treated migraine attacks over a one year period. The long-term data generated in this trial reinforced the well-tolerated safety profile and strong efficacy results previously reported in the six-month dosing portion of this safety study and in the randomized Phase 2/3 ZOTRIP pivotal study. Throughout the clinical program, over 5,800 migraine attacks have been treated with Qtrypta to date.
In this post-hoc analysis, researchers examined the efficacy of Qtrypta™ in treating subsets of patients whose migraines have traditionally been difficult-to-treat and have been associated with poorer outcomes when treated with oral medications. Migraine characteristics including severe pain, duration of migraine of more than 2 hours, awakening with migraine, and the presence of nausea are established factors that predict a poorer response to traditional migraine treatment.
Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the appointment of Linda Grais, M.D., J.D. to its board of directors. Dr. Grais brings a diverse and important set of experience and expertise to Zosano. After graduation from Yale Medical School and residency at UCSF, she was an assistant professor at UCSF in internal medicine, received her J.D. from Stanford Law School where she was an editor of Stanford Law and Policy Review before joining Wilson Sonsini Goodrich & Rosati as an associate representing Life Science companies.
Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proposed brand name Qtrypta™ for M207, the Company’s investigational drug for treatment of migraine. A request for proprietary name review and final approval for Qtrypta will be included when Zosano submits a New Drug Application (NDA) for M207. The name Qtrypta (pronounced "kew-trip-tah") was developed in compliance with the FDA's Guidance for Industry, Contents of a Complete Submission for the Evaluation of Proprietary Names. The proprietary name development program included research with physicians and pharmacists, and FDA’s conditional approval validated Qtrypta is a proprietary name that is consistent with the FDA's goal of preventing medication errors and potential harm to the public by ensuring that only appropriate proprietary names are approved for use. Final approval of the Qtrypta brand name is conditional on FDA approval of the product candidate, M207.
Selected a contract manufacturer for commercial launch of M207Completed first required data set in long-term safety study of M207Appointed Greg Kitchener as Chief Financial.
Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast to be held on Wednesday, November 14, 2018 at 4:30PM ET. The Company will announce its financial results for this period in a press release to be issued prior to the call. To access the live webcast, please visit the Investor Relations page of the Zosano Pharma website at http://ir.zosanopharma.com/events.cfm.